

AMENDMENTS TO THE SPECIFICATION

Please add the following to page 2, after the Background of the Invention and before the Summary of the Invention:

Brief Description of the Drawings

Figure 1 shows the response of the NCCIT, human testicular carcinoma cell line, to anti-CFC blocking Cripto mAb A8G3.5.

Figure 2 shows the response of the NCCIT, human testicular carcinoma cell line, to anti-EGF blocking Cripto mAb A27F6.1.

Figure 3 depicts the results of the FACS analysis showing 293/ALK4 cells binding CR-Fc.